Gain Therapeutics (GANX) risk factors, FY2024 10-K

Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization

1. 01We are subject to extensive and costly government regulation, which are subject to change
2. 02Our long-term success depends heavily on our ability to fund and complete research and development activities and obtain regulatory approval for our product candidates
3. 03Delays in preclinical studies and clinical trials could significantly increase our product development costs and delay product commercialization. In addition, many of the factors that may cause or lead to a delay in the clinical trials may also ultimately lead to denial of regulatory approval of a product candidate
4. 04Some of the disorders we seek to treat have low prevalence and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue if approved, and we may also face enrollment challenges as a result of other factors
5. 05Our product candidates are novel and still in development. If we are unable to successfully develop, receive regulatory approval for and commercialize our current or future product candidates, our business will be harmed
6. 06Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials
7. 07The approach we are taking to discover and develop our product candidates is novel and may never lead to marketable products
8. 08We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
9. 09Clinical trials required for our product candidates are expensive and time-consuming, and their outcome is uncertain
10. 10We have limited experience as a company conducting clinical trials and may be unable to complete pivotal clinical trials for any product candidates we may develop
11. 11If we decide to pursue a Fast Track Designation or comparable foreign regulatory procedures for some of our product candidates, it may not lead to a faster development or regulatory review or approval process
12. 12If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity
13. 13We do not have, and may never obtain, the regulatory approvals we need to market our product candidates
14. 14Our product candidates may cause serious adverse events (“SAEs”) or undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales
15. 15Even if approved, our products will be subject to extensive post-approval regulation
16. 16Even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market

Risks Related to Our Financial Condition and Capital Requirements; Competition

1. 17We face intense competition in the markets targeted by our product candidates. Many of our competitors have substantially greater resources than we do and we expect that all our product candidates under development will face intense competition from existing or future drugs
2. 18Competition and technological change may make our product candidates and technologies less attractive or obsolete
3. 19Our business and operations may be adversely affected by health epidemics or pandemics

Risks Related to Our Intellectual Property

1. 20Our success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our products and technologies
2. 21If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected
3. 22We may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming
4. 23If we infringe the rights of third parties, we could be prevented from selling products or forced to pay damages and defend against litigation

Risks Related to Third Parties and Collaborators

1. 24We currently rely on, and intend to rely on in the future, third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business
2. 25Third-party manufacturers must be inspected by the FDA and comparable foreign regulatory authorities for cGMP compliance before they can produce commercial products
3. 26Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of our products
4. 27Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results
5. 28Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete
6. 29Global and macroeconomic conditions, including economic, political and social instability, could adversely affect our financial condition or results of operations
7. 30We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth
8. 31We depend upon our key personnel and our ability to attract and retain qualified employees
9. 32Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees
10. 33Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws
11. 34Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved
12. 35Healthcare legislative reform measures may have a negative impact on our business and results of operations
13. 36Other legislative changes have been proposed and adopted since the ACA was enacted including aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2032 unless additional Congressional action is taken
14. 37If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business
15. 38governments, persons, entities, countries and territories including those that are the target of comprehensive sanctions or an embargo
16. 39Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop
17. 40Issues relating to the use of AI and machine learning could adversely affect our business and operating results
18. 41other partners may be adversely affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget

Risks Related to Ownership of Our Common Stock

1. 42The market price for our common stock has been and likely will continue to be volatile, and your investment in our securities could decline in value
2. 43We incur and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
3. 44We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors
4. 45Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
5. 46Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations
6. 47We do not anticipate paying dividends on our common stock and, accordingly, stockholders must rely on stock appreciation for any return on their investment
7. 48Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
8. 49The rights of the holders of our securities may be impaired by the potential issuance of preferred stock
9. 50If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline
10. 51Anti-takeover provisions in our organizational documents and Delaware law might discourage or delay attempts to acquire us that you might consider favorable
11. 52Provisions in our organizational documents regarding exculpation and indemnification of our directors and officers may result in substantial expenditures by us and may discourage lawsuits against our directors and officers